Geographic Region Variation in Patient Characteristics, Clinical Outcomes and Treatment of HFrEF in the VICTORIA Trial
Geographic variation in the phenotype of patients with HFrEF, standard of care, and clinical outcomes was observed, while there was no intra-regional heterogeneity in vericiguat's treatment effect. However, when considering contextual/systemic measures via country-level HDI, further insights into treatment effect were revealed. Country-level measures may be helpful in the planning of future trials and in the translation of evidence into practice.
Authors
- Justin Adrian Ezekowitz (ORCID: https://orcid.org/0000-0002-2724-4086)
- Stefano Corda (ORCID: https://orcid.org/0000-0002-8765-2444)
- Paul W. Armstrong (ORCID: https://orcid.org/0000-0002-0460-3445)
- Ciaran J. McMullan (ORCID: https://orcid.org/0000-0001-7269-6391)
- Wendimagegn Alemayehu (ORCID: https://orcid.org/0000-0002-8549-7962)
- Alain Cohen‐Solal (ORCID: https://orcid.org/0000-0003-1055-2231)
- Cynthia M. Westerhout (ORCID: https://orcid.org/0000-0003-1082-5981)
- Carolyn Lam
- Christopher M. O’Connor (ORCID: https://orcid.org/0000-0002-1076-718X)
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- University of Alberta (CA)
- Inserm (FR)
- National University of Singapore (SG)
- Université Paris Cité (FR)
- Sorbonne Paris Cité (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- National University Heart Centre Singapore (SG)
- Canadian VIGOUR Centre (CA)
- Bayer (Switzerland) (CH)
- Hôpital Lariboisière (FR)
- National Heart Centre Singapore (SG)
- Alaska Heart and Vascular Institute (US)
Publication Details
- Journal
- ESC Heart Failure
- Published
- 2025-09-22
- DOI
- https://doi.org/10.1002/ehf2.15416
- Citations
- 1
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- Bayer
- Duke Clinical Research Institute